Biofrontera INC Form 4 insider transactions

Hermann Luebbert, CEO & Chairman and a Director of Biofrontera Inc., reported multiple transactions in common stock on July 28, 2026.

Eugene Frederick Leffler, Chief Financial Officer of Biofrontera Inc., reported multiple transactions in common stock on July 28, 2026.

Biofrontera Inc. Director Kevin Daniel Weber reported the acquisition of 20,000 employee stock options with an exercise price of $0.90.

Biofrontera Inc. CEO and Chairman Hermann Luebbert acquired common stock and received new equity awards, including restricted stock units and stock options.

Biofrontera Inc.'s Chief Financial Officer, Eugene Frederick Leffler, received new grants of restricted stock units and stock options, alongside the conversion of previously awarded restricted stock units into common shares.

Biofrontera Inc. Director Heikki Lanckriet was granted 20,000 employee stock options with an exercise price of $0.9, vesting monthly over one year.

Biofrontera Inc. Director Beth J. Hoffman was granted 20,000 employee stock options with an exercise price of $0.90, vesting monthly over one year.

Biofrontera Inc.'s Chief Commercial Officer, George Patrick Jones, was granted 50,000 Restricted Stock Units and 50,000 employee stock options on March 4, 2026.

Biofrontera Inc. Director John J. Borer III was granted 20,000 employee stock options with an exercise price of $0.90, vesting monthly over one year.

Biofrontera AG, a 10% owner and director, acquired 3,019 Series D Convertible Preferred Stock in Biofrontera Inc. through an asset exchange.

Biofrontera Inc.'s Chief Commercial Officer, George Patrick Jones, was granted 100,000 employee stock options with an exercise price of $1 per share, vesting in two installments.

Biofrontera Inc. Director Kevin Daniel Weber was granted 20,000 employee stock options with an exercise price of $1, vesting over 12 months.

Biofrontera Inc. CEO Hermann Luebbert reported significant changes in his beneficial ownership, including the conversion of restricted stock units and new equity awards.

Biofrontera Inc.'s Chief Financial Officer, Eugene Frederick Leffler, reported significant equity transactions including the conversion of restricted stock units and new awards of restricted stock units and stock options.

Biofrontera Inc. Director Heikki Lanckriet was granted 20,000 employee stock options with a $1 exercise price, vesting monthly from August 2025.

Biofrontera Inc. Director Beth J. Hoffman was granted 20,000 employee stock options with an exercise price of $1, vesting monthly starting August 22, 2025.

Biofrontera Inc. Director and 10% owner John J. Borer III acquired 20,000 employee stock options with a $1 exercise price, vesting monthly from August 2025.

Kevin Daniel Weber, a director at Biofrontera Inc., acquired 20,000 employee stock options on July 12, 2024.

Heikki Lanckriet, a director of Biofrontera Inc., acquired 20,000 employee stock options on July 12, 2024.

Director Beth J. Hoffman acquired 20,000 employee stock options in Biofrontera Inc. on July 12, 2024.

Biofrontera Inc.'s CFO, Eugene Frederick Leffler III, received 175,000 restricted stock units and stock options as part of an award.

Director John J. Borer III of Biofrontera Inc. reports the acquisition of employee stock options.

Biofrontera Inc. CEO Hermann Luebbert receives stock options and restricted stock units as compensation.

CEO Hermann Luebbert reports the conversion of restricted stock units into common stock and subsequent disposal of shares on May 18, 2024.